Gefticip 250mg

Gefticip is a medication used to treat non-small cell lung cancer (NSCLC) in patients with certain types of mutations in the epidermal growth factor receptor (EGFR) gene. It is an oral medication that works by blocking the activity of the EGFR protein, which can help to slow down the growth of cancer cells. Here are some key points about the product:

Composition:

Gefticip contains Gefitinib, a medication that is a selective inhibitor of EGFR tyrosine kinase.

Indications:

Gefticip is indicated for the treatment of:

1. Locally advanced or metastatic NSCLC in patients with EGFR mutations in the tyrosine kinase domain of the EGFR gene
2. Locally advanced or metastatic NSCLC in patients who have failed previous chemotherapy

Mechanism of Action:

Gefitinib works by:

1. Binding to the EGFR protein and inhibiting its activity, which can help to slow down the growth of cancer cells
2. Reducing the production of proteins that promote cell growth and survival

Dosage and Administration: The recommended dosage of Gefticip is:

• 250mg taken orally once daily, with or without food
• The dose should be taken at the same time each day
• The medication should be taken continuously until disease progression or unacceptable toxicity

Side Effects:

Common side effects of Gefticip include:

1. Diarrhea
2. Fatigue
3. Nausea and vomiting
4. Skin rash
5. Acne
6. Muscle and bone pain
7. Increased risk of liver damage

Serious side effects can include:

1. Severe allergic reactions
2. Interstitial lung disease (ILD)
3. Pneumonitis (inflammation of the lungs)
4. Hepatotoxicity (liver damage)
5. Pancreatitis (inflammation of the pancreas)

Contraindications:

Gefticip is contraindicated in patients with:

1. Hypersensitivity to Gefitinib
2. Pregnancy or breastfeeding
3. Severe liver or kidney disease
4. Active bleeding or bleeding disorder

Precautions:

1. Patients with a history of liver or kidney disease should be closely monitored while receiving Gefticip.
2. Patients with a history of bleeding or bleeding disorders should be closely monitored while receiving Gefticip.
3. Patients with a history of liver damage should be closely monitored while receiving Gefticip.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of diarrhea or abdominal pain.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.